Status:
TERMINATED
Improved Estimation of GFR by Cystatin C in Preventing Contrast Induced Nephropathy by NAC or Zn
Lead Sponsor:
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Conditions:
Chronic Kidney Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background Prevention of contrast media (CM) induced nephropathy (CIN) by pharmacological prophylaxis (e.g. N-acetylcysteine; NAC) is controversially discussed. So far, in all interventional studies a...
Detailed Description
In a prospective, placebo-controlled, double blind trial patients with moderate impaired kidney function receiving hypoosmolar, nonionic contrast medium were randomly assigned to an oral treatment for...
Eligibility Criteria
Inclusion
- older than 18 years of age,
- serum creatinine \> 1.2 mg/dl or a creatinine clearance \< 50 ml/min (measured by a 12 or 24 hour urine collection).
Exclusion
- acute inflammatory disease,
- medication with NSAID or metformin until 3 days before entering study,
- abnormal findings in physical examinations, e.g. signs of dehydration or decompensated heart failure.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00399256
Start Date
March 1 2004
End Date
March 1 2006
Last Update
February 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert-Bosch-Hospital
Stuttgart, Germany, D-70376